Discover how a clinical trial overcame patient enrollment challenges by addressing PI expertise misalignment and leveraging data-driven referral tools.

Digital health solutions are increasingly common in healthcare, with over
300,000 health apps available and more than half of U.S. adults using
digital health tools.

Unlock the Value of Effective Treatments: Discover how life sciences leaders can optimize patient outcomes and healthcare costs by addressing key questions about treatment adherence, healthcare utilization, and cost reduction.

Unlock unparalleled commercial success with PurpleLab®’s cutting-edge data analytics and real-world insights.

The healthcare landscape is more complex than ever – and pharmaceutical companies are feeling the pressure. From pre-commercial drug development to post-launch performance, success hinges on a deep understanding of the full patient journey. However, traditional approaches to patient mapping often miss the nuanced factors that shape real-world health outcomes. Enter real-world data (RWD) enriched…

Cancer survival rates have improved dramatically over the past few decades thanks to ongoing advances in therapeutics. As research continues to push the boundaries of medicine, two innovative technologies stand out in the fight against cancer: Antibody-Drug Conjugates (ADCs) and PROteolysis TArgeting Chimeras (PROTACs). These cutting-edge approaches are refining how we treat cancer and opening…

Mapping the patient journey has become more complex, but also more critical to understand what is actually happening in the treatment or therapeutic landscape. This webinar will explore how leveraging PurpleLab’s integrated data sources, including claims and Social Determinants of Health (SDOH), can unlock critical insights for commercial, market access, and medical affairs teams.

Learn more about what PurpleLab can do for Clinical Trials Life Sciences Download

The Give Kids a Chance Act of 2025 is a piece of legislation poised to transform drug development for children with rare diseases and cancer. Reintroduced in the House of Representatives on February 12, 2025, by Congressman Michael McCaul, this bipartisan effort aims to extend the Priority Review Voucher (PRV) program beyond its anticipated September…